Reference : Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Fi...
Scientific journals : Article
Human health sciences : Hematology
Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
Baron, Frédéric mailto [Université de Liège - ULg > > GIGA-R : Hématologie >]
Suciu, Stefan [EORTC Headquarters (Brussels) > >]
Amadori, Sergio [Tor Vergata University Hospital (Rome, Italy) > >]
Muus, Petra [Radboud University Nijmegen Medical Centre (The Netherlands) > >]
Zwierzina, Heinz [Medizinische Universitätsklinik (Innsbruck, Austria) > >]
Denzlinger, Claudio [Medical Clinic III (Stuttgart, Germany) > >]
Delforge, Michel [University Hospital Gasthuisberg (Leuven, Belgium) > >]
Thyss, Antoine [Centre Antoine-Lacassagne (Nice, France) > >]
Selleslag, Dominik [Algemeen Academisch Ziekenhuis St Jan (Bruges-Oostende, Belgium) > >]
Indrak, Karel [University Hospital Olomouc (Czech Republic) > >]
Ossenkoppele, Geert [Vrije Universiteit Medical Centre (Amsterdam, The Netherlands) > >]
De Witte, Theo [Medizinische Universitätsklinik (Innsbruck, Austria) > >]
Ferrata Storti Foundation
Yes (verified by ORBi)
[en] infliximab ; tumor necrosis factor alpha ; MDS ; myelodysplastic syndrome ; phase II ; randomized
[en] Tumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade) is an anti-tumor-necrosis factor alpha chimeric antibody that is used in the treatment of patients with heumatoid arthritis or Crohn's disease. Forty-six patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg versus 5 mg/kg). The primary endpoint was the response rate. Responses were observed in 3 of 22 patients (13.1%) randomized to the 3 mg/kg arm, versus 0 of 21 patients randomized in the 5 mg/kg arm. According to the statistical design of the current study, neither of the two infliximab dose schedules tested showed sufficient activity as a single agent in this cohort of unselected patients with early myelodysplastic syndrome.

File(s) associated to this reference

Fulltext file(s):

Open access
Remicade_EORTC_Haematologica2012.pdfPublisher postprint363.4 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.